Triple

T19773599
Position Surface form Disambiguated ID Type / Status
Subject Teva Pharmaceutical Industries E474949 entity
Predicate acquired P2511 FINISHED
Object Ivax Corporation NE NERFINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Ivax Corporation | Statement: [Teva Pharmaceutical Industries, acquired, Ivax Corporation]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Ivax Corporation
Context triple: [Teva Pharmaceutical Industries, acquired, Ivax Corporation]
  • A. Teva Pharmaceutical Industries
    Teva Pharmaceutical Industries is a global pharmaceutical company based in Israel, best known as one of the world’s largest manufacturers of generic medicines and a producer of specialty and over-the-counter drugs.
  • B. Millennium Pharmaceuticals
    Millennium Pharmaceuticals is a biotechnology company known for developing innovative cancer therapies, including the proteasome inhibitor bortezomib (Velcade) for multiple myeloma.
  • C. Lambert Pharmaceutical Company
    Lambert Pharmaceutical Company was a pharmaceutical firm associated with American aviator and businessman Albert Bond Lambert, known for its role in his early business career.
  • D. Alkermes
    Alkermes is a biopharmaceutical company that develops innovative medicines for central nervous system disorders and other serious chronic diseases.
  • E. Gland Pharma
    Gland Pharma is an Indian pharmaceutical company specializing in injectable formulations and contract manufacturing for global markets.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: Ivax Corporation
Target entity description: Ivax Corporation was a multinational generic and specialty pharmaceutical company known for developing and marketing a wide range of prescription and over-the-counter medicines before its acquisition by Teva.
  • A. Teva Pharmaceutical Industries chosen
    Teva Pharmaceutical Industries is a global pharmaceutical company based in Israel, best known as one of the world’s largest manufacturers of generic medicines and a producer of specialty and over-the-counter drugs.
  • B. Millennium Pharmaceuticals
    Millennium Pharmaceuticals is a biotechnology company known for developing innovative cancer therapies, including the proteasome inhibitor bortezomib (Velcade) for multiple myeloma.
  • C. Lambert Pharmaceutical Company
    Lambert Pharmaceutical Company was a pharmaceutical firm associated with American aviator and businessman Albert Bond Lambert, known for its role in his early business career.
  • D. Alkermes
    Alkermes is a biopharmaceutical company that develops innovative medicines for central nervous system disorders and other serious chronic diseases.
  • E. Gland Pharma
    Gland Pharma is an Indian pharmaceutical company specializing in injectable formulations and contract manufacturing for global markets.
  • F. None of above.

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d8e51a43a08190956bc6df13c91a77 completed April 10, 2026, 11:55 a.m.
NER Named-entity recognition batch_69e6535e450c8190a2628245ae0d0bd3 completed April 20, 2026, 4:25 p.m.
Created at: April 10, 2026, 1:48 p.m.